Literature DB >> 15734162

Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization.

Mark S Schmidt1, Thomas E Prisinzano, Kevin Tidgewell, Wayne Harding, Eduardo R Butelman, Mary J Kreek, Daryl J Murry.   

Abstract

Salvinorin A was quantitated in human and rhesus monkey plasma, rhesus monkey cerebrospinal fluid, and human urine by negative ion LC-MS/APCI. The method for Salvinorin A has been fully validated, the LLOQ using FDA guidelines is 2 ng/mL for 0.5 mL plasma samples. The linear range was from 2 to 1000 ng/mL. Several derivatives in the Salvinorin family can also be analyzed by this method; d(3)-Salvinorin A was prepared and used as internal standard. The metabolite Salvinorin B can be semi quantitatively determined. The method has been used to establish that Salvinorin B is the principal metabolite of Salvinorin A ex vivo and to establish the analytical method to study in vivo samples.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734162     DOI: 10.1016/j.jchromb.2004.12.041

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  15 in total

Review 1.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

2.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

Review 3.  Neoclerodanes as atypical opioid receptor ligands.

Authors:  Thomas E Prisinzano
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

4.  Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.

Authors:  Ryan Vandrey; Matthew W Johnson; Patrick S Johnson; Miral A Khalil
Journal:  Adolesc Psychiatry (Hilversum)       Date:  2013-04

5.  LC-MS/MS quantification of salvinorin A from biological fluids.

Authors:  Michael J Caspers; Todd D Williams; Kimberly M Lovell; Anthony Lozama; Eduardo R Butelman; Mary Jeanne Kreek; Matthew Johnson; Roland Griffiths; Katherine Maclean; Thomas E Prisinzano
Journal:  Anal Methods       Date:  2013-12-21       Impact factor: 2.896

Review 6.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

Review 7.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

Review 8.  Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.

Authors:  Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

9.  Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.

Authors:  Jacob M Hooker; Youwen Xu; Wynne Schiffer; Colleen Shea; Pauline Carter; Joanna S Fowler
Journal:  Neuroimage       Date:  2008-03-15       Impact factor: 6.556

10.  Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A.

Authors:  S Inan; D Y-W Lee; L Y Liu-Chen; A Cowan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.